International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases

Международные клинические руководства по лечению острого неосложнённого цистита и пиелонефрита у женщин: обновление 2010 г. от Общества инфекционных заболеваний США и Европейского общества по микробиологии и инфекционным болезням
David E. Soper, Gregory J. Moran, Thomas M. Hooton, Anthony J. Schaeffer, Lindsay E. Nicolle, Kurt G. Naber, Kalpana Gupta, Björn Wullt, Richard Colgan, Loren G. Miller, Raul Raz
2011-02-03

IDSA-ESCMID guidelinesacute uncomplicated cystitisantimicrobial resistance prevalenceecological adverse effects (collateral damage)pyelonephritis in women
A Panel of International Experts was convened by the Infectious Diseases Society of America (IDSA) in collaboration with the European Society for Microbiology and Infectious Diseases (ESCMID) to update the 1999 Uncomplicated Urinary Tract Infection Guidelines by the IDSA. Co-sponsoring organizations include the American Congress of Obstetricians and Gynecologists, American Urological Association, Association of Medical Microbiology and Infectious Diseases-Canada, and the Society for Academic Emergency Medicine. The focus of this work is treatment of women with acute uncomplicated cystitis and pyelonephritis, diagnoses limited in these guidelines to premenopausal, non-pregnant women with no known urological abnormalities or co-morbidities. The issues of in vitro resistance prevalence and the ecological adverse effects of antimicrobial therapy (collateral damage) were considered as important factors in making optimal treatment choices and thus are reflected in the rankings of recommendations.
1
An international expert panel (IDSA and ESCMID) updated 1999 guidelines for treating acute uncomplicated cystitis and pyelonephritis in women (2010).
2
Ecological adverse effects of antimicrobial therapy (collateral damage) were incorporated into recommendation rankings.
3
Guidelines focus specifically on premenopausal, non-pregnant women without urological abnormalities or co-morbidities.
4
In vitro antimicrobial resistance prevalence was explicitly considered when formulating treatment recommendations.
5
Multiple professional societies co-sponsored the update, including ACOG, AUA, AMMI-Canada, and SAEM, indicating broad clinical endorsement.

Premenopausal, non-pregnant women with acute uncomplicated cystitis and pyelonephritis (no known urological abnormalities or co-morbidities)

Clinical treatment recommendations for acute uncomplicated cystitis and pyelonephritis in this population, considering antimicrobial choice, in vitro resistance prevalence, and ecological adverse effects (collateral damage)

Publication Details
Publication Date
2011-02-03
Journal
Publisher
ISSN
Access Type
Author Information
Authors
David E. Soper
Gregory J. Moran
Thomas M. Hooton
Anthony J. Schaeffer
Lindsay E. Nicolle
Kurt G. Naber
Kalpana Gupta
Björn Wullt
Richard Colgan
Loren G. Miller
Raul Raz
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat
Make a presentation
100%